These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32366392)

  • 1. A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model.
    Lim HI; Yamamoto J; Inubushi S; Nishino H; Tashiro Y; Sugisawa N; Han Q; Sun YU; Choi HJ; Nam SJ; Kim MB; Lee JS; Hozumi C; Bouvet M; Singh SR; Hoffman RM
    Anticancer Res; 2020 May; 40(5):2481-2485. PubMed ID: 32366392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
    Yamamoto J; Murata T; Tashiro Y; Higuchi T; Sugisawa N; Nishino H; Inubushi S; Sun YU; Lim H; Miyake K; Hongo A; Nomura T; Saitoh W; Moriya T; Tanino H; Hozumi C; Bouvet M; Singh SR; Endo I; Hoffman RM
    Anticancer Res; 2020 May; 40(5):2509-2514. PubMed ID: 32366395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.
    Yamamoto J; Murata T; Sugisawa N; Higuchi T; Tashiro Y; Nishino H; Inubushi S; Sun YU; Lim H; Miyake K; Shimoya K; Nomura T; Kurebayashi J; Tanino H; Hozumi C; Bouvet M; Singh SR; Endo I; Hoffman RM
    Anticancer Res; 2020 May; 40(5):2475-2479. PubMed ID: 32366391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Oral Recombinant Methioninase and Eribulin on a PDOX Model of Triple-negative Breast Cancer (TNBC) Liver Metastasis.
    Lim HI; Sun YU; Han Q; Yamamoto J; Hoffman RM
    In Vivo; 2021; 35(5):2531-2534. PubMed ID: 34410939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
    Miyake K; Murakami T; Kiyuna T; Igarashi K; Kawaguchi K; Li Y; Singh AS; Dry SM; Eckardt MA; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Endo I; Eilber FC; Hoffman RM
    J Cell Biochem; 2018 Jan; 119(1):967-972. PubMed ID: 28681998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models.
    Guo Z; Luo J; Mashl RJ; Hoog J; Maiti P; Fettig N; Davies SR; Aft R; Held JM; Govindan R; Ding L; Li S; von Morze C; Wulf GM; Shoghi KI; Ma CX
    Cancer Res Commun; 2024 Jun; 4(6):1430-1440. PubMed ID: 38717161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.
    Xiang J; Hurchla MA; Fontana F; Su X; Amend SR; Esser AK; Douglas GJ; Mudalagiriyappa C; Luker KE; Pluard T; Ademuyiwa FO; Romagnoli B; Tuffin G; Chevalier E; Luker GD; Bauer M; Zimmermann J; Aft RL; Dembowsky K; Weilbaecher KN
    Mol Cancer Ther; 2015 Nov; 14(11):2473-85. PubMed ID: 26269605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Case of Rare Matrix-producing Triple-negative Breast Carcinoma for Which Drug Response in a Patient-derived Orthotopic Xenograft Mouse Model Was Correlated With Patient Response.
    Nomura T; Kurebayashi J; Moriya T; Saito W; Murata T; Yamamoto J; Hozumi C; Hoffman RM
    Anticancer Res; 2021 Dec; 41(12):6191-6197. PubMed ID: 34848473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
    Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
    Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
    Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Higuchi T; Yamamoto N; Hayashi K; Kimura H; Miwa S; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Genomics Proteomics; 2020; 17(4):351-358. PubMed ID: 32576580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
    Arango NP; Yuca E; Zhao M; Evans KW; Scott S; Kim C; Gonzalez-Angulo AM; Janku F; Ueno NT; Tripathy D; Akcakanat A; Naing A; Meric-Bernstam F
    Breast Cancer Res; 2017 Aug; 19(1):93. PubMed ID: 28810913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of Triple-negative Breast Cancer Liver Metastasis to Oral Recombinant Methioninase in a Patient-derived Orthotopic Xenograft (PDOX) Model.
    Lim HI; Yamamoto J; Han Q; Sun YU; Nishino H; Tashiro Y; Sugisawa N; Tan Y; Choi HJ; Nam SJ; Bouvet M; Hoffman RM
    In Vivo; 2020; 34(6):3163-3169. PubMed ID: 33144420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Methioninase Inhibits Recurrence in a PDOX Mouse Model of Aggressive Triple-negative Breast Cancer.
    Lim HI; Hamada K; Yamamoto J; Han Q; Tan Y; Choi HJ; Nam SJ; Bouvet M; Hoffman RM
    In Vivo; 2020; 34(5):2281-2286. PubMed ID: 32871751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eribulin Inhibits Osteosarcoma in a Clinically-accurate Bone-tumor-insertion PDOX Mouse Model.
    Wu NF; Yamamoto J; Aoki Y; Bouvet M; Hoffman RM
    Anticancer Res; 2021 Apr; 41(4):1779-1784. PubMed ID: 33813382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.
    Ramani VC; Lemaire CA; Triboulet M; Casey KM; Heirich K; Renier C; Vilches-Moure JG; Gupta R; Razmara AM; Zhang H; Sledge GW; Sollier E; Jeffrey SS
    Breast Cancer Res; 2019 Aug; 21(1):98. PubMed ID: 31462307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteosarcoma of the Breast in a Patient Derived Orthotopic Xenograft (PDOX) Mouse Model Is Arrested by both Cisplatinum and Eribulin.
    Masaki N; Wu NF; Aoki Y; Yamamoto J; Miyazaki J; Hoffman RM
    In Vivo; 2021; 35(6):3107-3110. PubMed ID: 34697141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
    Kiyuna T; Tome Y; Miyake K; Murakami T; Oshiro H; Igarashi K; Kawaguchi K; Hsu J; Singh M; Li Y; Nelson S; Bouvet M; Singh SR; Kanaya F; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4775-4779. PubMed ID: 31519578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Noda S; Takashima T; Onoda N; Tomita S; Ohsawa M; Hirakawa K; Ohira M
    PLoS One; 2017; 12(2):e0170634. PubMed ID: 28166544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate.
    Bräutigam K; Mitzlaff K; Uebel L; Köster F; Polack S; Pervan M; Steinert G; Rody A; Liedtke C
    Anticancer Res; 2016 Jun; 36(6):2759-66. PubMed ID: 27272786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting.
    Mougalian SS; Copher R; Kish JK; McAllister L; Wang Z; Broscious M; Garofalo D; Radtchenko J; Feinberg BA
    Cancer Med; 2018 Sep; 7(9):4371-4378. PubMed ID: 30066497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.